Oncogenic protein tyrosine kinases

@article{Saglio2004OncogenicPT,
  title={Oncogenic protein tyrosine kinases},
  author={G. Saglio and D. Cilloni},
  journal={Cellular and Molecular Life Sciences CMLS},
  year={2004},
  volume={61},
  pages={2897-2911}
}
  • G. Saglio, D. Cilloni
  • Published 2004
  • Biology
  • Cellular and Molecular Life Sciences CMLS
    • Abstract.Since it was first recognized, chronic myeloid leukemia (CML) has always represented a unique model to understand the molecular mechanisms underlying the onset and progression of a leukemic process. CML was the first recognized form of cancer to have a strong association with a recurrent chromosomal abnormality, the t(9;22) translocation, which generates the so-called Philadelphia (Ph)-chromosome. Twenty years later, this abnormality was shown to cover a specific molecular defect, a… CONTINUE READING
    View on Springer
    11 Citations
    Background Citations
    1

    Figures from this paper

    Figures

    11 Citations
    Citation Type

    Citation Type

    BCR-ABL and Human Cancer
    • 8
    30 – Hematopoietic Cancers
    Inhibitors of signal transduction protein kinases as targets for cancer therapy.
    • 23
    ArgBP2-dependent signaling regulates pancreatic cell migration, adhesion, and tumorigenicity.
    • 38
    • PDF
    Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads.
    • 11
    Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway
    • 57
    • PDF
    Analysis of Bcr‐Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P‐loop and T315I mutation is disease phase dependent
    • 42
    Regulation of Cell Motility by Abl Family Kinases
    • 2
    Peptide reporters of kinase activity in whole cell lysates.
    • 29
    Study of Abl1 tyrosine kinase inhibitors by liquid chromatography-electrospray ionization-mass spectrometry.
    • 8

    References

    SHOWING 1-10 OF 121 REFERENCES
    The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.
    • 729
    • PDF
    Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.
    • 295
    BCR/ABL transcripts and leukemia phenotype: an unsolved puzzle.
    • 22
    Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
    • 3,002
    • PDF
    Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
    • 88
    • PDF
    Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
    • 896
    • PDF
    Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
    • 387
    Evidence for a multistep pathogenesis of chronic myelogenous leukemia.
    • 221
    • PDF
    Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    • 2,661
    • PDF
    Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    • 4,755
    • PDF